Prof. PeptideProf. Peptide

Everything you need for peptide research, in one place

72

Peptide profiles

75

Compounds compared

210

Verified discount codes

100%

Independent research

Certificates lab-checked in the last 7 days, as of November 15, 2026: Peptix USA, AminoHaus, LabSourced and 10 more.

Prof. Peptide provides peptide research for educational purposes only. Nothing on this site constitutes medical advice or endorses human use of research peptides.

Everything a researcher needs

From peptide mechanisms to reconstitution math — Prof. Peptide covers it all, clearly and credibly.

Latest News

View all news

November 15, 2026

CagriSema REDEFINE 9 Results: 21% Weight Loss at Lower Doses

REDEFINE 9 (The Lancet Diabetes & Endocrinology, November 14, 2026) randomized 309 adults with overweight or obesity and no diabetes to CagriSema 1.7 mg or 1.0 mg each or placebo for 68 weeks. Body weight fell 20.7% and 21.0% versus 2.0% with placebo on the efficacy estimand. Novo's release, company-reported, gives the treatment-regimen results and a fourth-quarter 2026 FDA decision expected for the 2.4 mg dose.

Read more →

November 7, 2026

Is CagriSema Better Than Semaglutide? A Type 2 Diabetes Meta-Analysis Finds the Edge Is Weight, Not Blood Sugar

A Bayesian meta-analysis of six randomized trials in type 2 diabetes (Diabetes, Obesity & Metabolism, October 27, 2026): against semaglutide 2.4 mg, CagriSema lowered body weight a further 5.84 points (95% CrI -10.08 to -2.15), while the extra HbA1c reduction, -0.21 points, had an interval crossing zero. Against placebo, gastrointestinal events and adverse-event discontinuations were more common.

Read more →

November 6, 2026

Retatrutide for Sleep Apnea: Two Phase 3 Trials in the NEJM Report Lower Apnea-Hypopnea Index Scores

The New England Journal of Medicine published TRIUMPH-1-OSA (243 adults without type 2 diabetes) and TRIUMPH-2-OSA (448 with it) on October 21, 2026. At 80 weeks the apnea-hypopnea index changed by up to -34.3 and -25.4 events per hour with retatrutide versus about -10 with placebo. The results on both estimands, how they sit beside tirzepatide's approved sleep apnea indication, and Lilly's company-reported ObesityWeek 2026 figures (November 14) for sleep apnea and for knee osteoarthritis pain in TRIUMPH-1 and TRIUMPH-4.

Read more →
Why Prof. Peptide

Built for researchers

Most peptide sites exist to sell products. Prof. Peptide exists to educate. We're independent, ad-light, and committed to presenting research accurately — including limitations and unknowns.

  • ✓Content is editorially independent and research-driven
  • ✓Every peptide profile cites primary research literature
  • ✓Calculator math is transparent and peer-reviewable
  • ✓Discount codes are manually verified before publishing

Now on iOS

The all-in-one peptide tracker

Log doses, see estimated levels, calculate reconstitution, and search 70+ peptides by name or brand — all in one private iOS app.

Get the App

Don't overpay for peptides.

Prof. Peptide finds the best deals and delivers them to your inbox.